Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12744859 | 0.74 | ALDH1A1 (0.37) | HTR1ADRD2HTR2AHTR7TSHR | |
| SCHEMBL16939998 | 0.72 | — | — | |
| SCHEMBL516158 | 0.72 | HTR1A (0.33) | HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL7247165 | 0.72 | HTR1A (0.33) | HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL15932247 | 0.72 | — | — | |
| SCHEMBL15907945 | 0.70 | HTR1A (0.39) | HTR1ADRD2HTR2AHTR7 | |
| Fluoride SCHEMBL775570 | 0.69 | HTR1A (0.32) | HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL21190314 | 0.69 | HTR1A (0.32) | HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL2517119 | 0.67 | HTR1A (0.31) | HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL19733766 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-11857603-B2 | PTH compounds with low peak-to-trough ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2024-01-02 | — | — | US | disclosed |
| US-20230381284-A1 | Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-11-30 | — | — | US | disclosed |
| US-20230364199-A1 | IMPROVEMENT OF PHYSICAL AND MENTAL WELL-BEING OF PATIENTS WITH HYPOPARATHYROIDISM | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-11-16 | — | — | US | disclosed |
| US-11793861-B2 | PTH prodrugs | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-10-24 | — | — | US | disclosed |
| US-20230321198-A1 | Dosage Regimen for a Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-10-12 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-11759504-B2 | PTH compounds with low peak-to-trough ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-09-19 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20110269786-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| WO-2011137390-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20100324313-A1 | METHOD FOR THE PURIFICATION OF PROSTAGLANDINS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2010-12-23 | — | — | US | disclosed |
| WO-2010081022-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | ANTHERA PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20090246211-A1 | Molecular constructs suitable for targeted conjugates | TAPESTRY PHARMACEUTICALS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-7494714-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2009-02-24 | — | — | US | disclosed |
| US-7414013-B2 | Sulfurized polyisobutylene based wear and oxidation inhibitors | CHEVRON ORONITE COMPANY LLC (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070264505-A1 | Resistant to the adsorption of proteins, cells and bacteria; have a chemical chain bonded thereon that comprise a terminal group free of a hydrogen bond donor or where a hydrogen bond donor is sufficiently buried | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-11-15 | — | — | US | disclosed |
| US-7276286-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364199-A1 | IMPROVEMENT OF PHYSICAL AND MENTAL WELL-BEING OF PATIENTS WITH HYPOPARATHYROIDISM | PTH1R, CRH, PTMS | HTR1A 561/4885DRD2 2044/4885HTR2A 243/4885 |
| US-11793861-B2 | PTH prodrugs | PTH1R, PTMS, PHPT1 | HTR1A 2638/4885DRD2 3679/4885HTR2A 2071/4885 |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | HTR1A 4483/4885DRD2 4160/4885HTR2A 4301/4885 |
| US-20110269786-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | PLAA, PLA2G12A, PLAAT2 | HTR1A 3182/4885DRD2 4366/4885HTR2A 1434/4885 |
| US-11759504-B2 | PTH compounds with low peak-to-trough ratios | PTH1R, PTMS, FGF23 | HTR1A 1634/4885DRD2 3480/4885HTR2A 1737/4885 |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | HTR1A 4510/4885DRD2 3803/4885HTR2A 3767/4885 |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SHH, GLI1, SMO | HTR1A 3631/4885DRD2 4814/4885HTR2A 3835/4885 |
| US-20230381284-A1 | Controlled-Release PTH Compound | PTH1R, CALCA, CALCB | HTR1A 1515/4885DRD2 2825/4885HTR2A 1743/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | HTR1A 3573/4885DRD2 4080/4885HTR2A 3340/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | HTR1A 1723/4885DRD2 1935/4885HTR2A 1128/4885 |
| US-11857603-B2 | PTH compounds with low peak-to-trough ratios | PTH1R, PTMS, FGF23 | HTR1A 1634/4885DRD2 3480/4885HTR2A 1737/4885 |
| US-20230321198-A1 | Dosage Regimen for a Controlled-Release PTH Compound | PTH1R, CALCB, AVPR2 | HTR1A 2344/4885DRD2 2004/4885HTR2A 1195/4885 |
| US-20090246211-A1 | Molecular constructs suitable for targeted conjugates | MRPL21, QSOX1, MLX | HTR1A 3025/4885DRD2 3525/4885HTR2A 3975/4885 |
| US-20100324313-A1 | METHOD FOR THE PURIFICATION OF PROSTAGLANDINS | PTGES, PTGES2, PTGS2 | HTR1A 4171/4885DRD2 1888/4885HTR2A 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.